Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.18 -2.1%	$1.59	$1.11 ▼ $3.78	$256.98M	0.6	3.29 million shs	7.59 million shs
ANIX Anixa Biosciences	$2.63 +1.2%	$2.79	$2.07 ▼ $4.20	$84.68M	0.43	91,533 shs	15,658 shs
AVTE Aerovate Therapeutics	$9.26 -8.2%	$76.91	$43.75 ▼ $884.98	$268.40M	0.95	18,040 shs	212,443 shs
SNDL SNDL	$1.31 +0.4%	$1.45	$1.26 ▼ $2.93	$342.92M	3.68	2.29 million shs	1.69 million shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-6.64%	-28.87%	-16.43%	-25.31%	-58.93%
ANIX Anixa Biosciences	-1.89%	-6.81%	+4.42%	-18.50%	-10.65%
AVTE Aerovate Therapeutics	-12.26%	-0.49%	-88.56%	-88.78%	-98.59%
SNDL SNDL	-1.15%	-13.09%	-2.63%	-32.90%	-48.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.3238 of 5 stars	3.5	3.0	3.2	4.2	0.6
ANIX Anixa Biosciences	1.5862 of 5 stars	3.6	3.0	0.0	1.7	0.0
AVTE Aerovate Therapeutics	1.5736 of 5 stars	3.0	0.0	3.6	1.7	0.6
SNDL SNDL	2.9324 of 5 stars	3.5	3.0	2.4	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$9.29	690.54% Upside
ANIX Anixa Biosciences	3.25	Buy	$9.00	242.21% Upside
AVTE Aerovate Therapeutics	2.00	Hold	$78.75	750.43% Upside
SNDL SNDL	3.00	Buy	$3.63	177.78% Upside

Current Analyst Ratings Breakdown

Latest ANIX, AVTE, SNDL, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/26/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/25/2025	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/21/2025	ANIX Anixa Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/19/2025	ALLO Allogene Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
3/19/2025	SNDL SNDL	ATB Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		$3.50 ➝ $4.00
3/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
3/14/2025	ALLO Allogene Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
2/18/2025	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	11,680.84	N/A	N/A	$3.04 per share	0.39
ANIX Anixa Biosciences	$210K	403.23	N/A	N/A	$0.59 per share	4.46
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
SNDL SNDL	$927.61M	0.37	N/A	N/A	$3.47 per share	0.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.33	N/A	N/A	N/A	N/A	-52.13%	-41.29%	5/12/2025 (Estimated)
ANIX Anixa Biosciences	-$12.55M	-$0.39	N/A	∞	N/A	N/A	-58.55%	-53.29%	6/3/2025 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	5/12/2025 (Estimated)
SNDL SNDL	-$127.91M	-$0.29	N/A	N/A	N/A	-12.11%	-8.27%	-6.96%	N/A

Latest ANIX, AVTE, SNDL, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	$0.00 million	N/A
5/12/2025	Q4 2024	AVTE Aerovate Therapeutics	-$0.30	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A
3/18/2025	Q4 2024	SNDL SNDL	-$0.01	-$0.19	-$0.18	-$0.19	$248.10 million	$179.06 million
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A
3/11/2025	Q1 2025	ANIX Anixa Biosciences	-$0.10	-$0.10	N/A	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Latest ANIX, AVTE, SNDL, and ALLO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
ANIX Anixa Biosciences	N/A	8.54	8.54
AVTE Aerovate Therapeutics	N/A	8.78	8.78
SNDL SNDL	0.10	5.61	4.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ANIX Anixa Biosciences	29.13%
AVTE Aerovate Therapeutics	N/A
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	24.30%
ANIX Anixa Biosciences	25.30%
AVTE Aerovate Therapeutics	24.90%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.71 million	158.72 million	Optionable
ANIX Anixa Biosciences	5	32.20 million	24.05 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
SNDL SNDL	580	262.78 million	N/A	Optionable

ANIX, AVTE, SNDL, and ALLO Headlines

Recent News About These Companies

SA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLI

May 5 at 11:01 PM | msn.com

SNDL (NASDAQ:SNDL) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

May 5 at 10:34 AM | marketbeat.com

SNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has Increased

May 5 at 1:12 AM | seekingalpha.com

Boothbay Fund Management LLC Takes Position in SNDL Inc. (NASDAQ:SNDL)

May 4, 2025 | marketbeat.com

SNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call Transcript

May 3, 2025 | insidermonkey.com

SNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

May 3, 2025 | finance.yahoo.com

3 Marijuana Stocks For The Long Term Investing

May 2, 2025 | marijuanastocks.com

SNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market Review

May 2, 2025 | uk.finance.yahoo.com

These Cannabis Companies Are Repurchasing Shares

May 2, 2025 | newcannabisventures.com

SNDL Inc. (SNDL) Q1 2025 Earnings Call Transcript

May 2, 2025 | seekingalpha.com

SNDL 1Q Loss Widens

May 2, 2025 | marketwatch.com

SNDL Inc. Earnings Call Highlights Growth and Challenges

May 1, 2025 | tipranks.com

SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates

May 1, 2025 | zacks.com

SNDL Reports Record Q1 2025 Results and Strategic Initiatives

May 1, 2025 | tipranks.com

SNDL Reports First Quarter 2025 Financial and Operational Results

May 1, 2025 | prnewswire.com

SNDL (SNDL) Projected to Post Earnings on Thursday

April 26, 2025 | marketbeat.com

SNDL Launches Rise Rewards Loyalty Program

April 22, 2025 | prnewswire.com

203,130 Shares in SNDL Inc. (NASDAQ:SNDL) Acquired by OneDigital Investment Advisors LLC

April 21, 2025 | marketbeat.com

SNDL Inc. to Acquire 32 Cannabis Retail Stores in Strategic Expansion

April 17, 2025 | tipranks.com

Cannabis operator SNDL now listing its stocks on Canadian Securities Exchange

April 15, 2025 | mjbizdaily.com

SNDL Inc. to Release Q1 2025 Financial Results on May 1

April 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX, AVTE, SNDL, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.18 -0.03 (-2.08%)

Closing price 03:59 PM Eastern

Extended Trading

$1.18 +0.01 (+0.85%)

As of 07:55 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Anixa Biosciences NASDAQ:ANIX

$2.63 +0.03 (+1.15%)

Closing price 03:57 PM Eastern

Extended Trading

$2.64 +0.00 (+0.19%)

As of 06:42 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Aerovate Therapeutics NASDAQ:AVTE

$9.26 -0.83 (-8.23%)

As of 05/7/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

SNDL NASDAQ:SNDL

$1.30 +0.01 (+0.38%)

Closing price 03:59 PM Eastern

Extended Trading

$1.30 0.00 (0.00%)

As of 07:58 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time